Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Andy Sheldon Named CEO of the Year by Vaccine Industry Excellence Awards at the World Vaccine Congress

April 12, 2012

QUEBEC CITY, April 12, 2012 /PRNewswire/ – Medicago Inc. (TSX: MDG), a
biopharmaceutical company focused on developing highly effective and
competitive vaccines based on proprietary manufacturing technologies
and Virus-Like Particles, announced today that Chief Executive Officer
Andy Sheldon was named “CEO of the Year” at the recently held World
Vaccine Congress in Washington, D.C. The Vaccine Industry Excellence
(ViE) Awards recognize the outstanding achievements of vaccine
practitioners and stakeholders across the global industry.

“I am honored to be selected as CEO of the Year, and sincerely thank
both the ViE judging panel and all who voted to support my nomination
for this award,” said Andy Sheldon, President and CEO of Medicago.
“Being chosen as the CEO of the Year is also an acknowledgement of the
Medicago team, and I share this award with all employees in recognition
of their dedication and industry-leading vision.  2011 was an important
year for Medicago, and I look forward to continuing to lead the Company
to advance our pipeline of plant-based product candidates to further
demonstrate our ability to rapidly develop highly effective and cost
effective vaccines.”

Medicago’s pipeline includes the initiation of a U.S. Phase IIa clinical
trial for a quadrivalent seasonal vaccine with interim data expected in
the first quarter of 2013.  A Phase I clinical trial for a one-dose
H5N1 VLP vaccine with a new adjuvant is planned for the second quarter
of 2012, in partnership with the Infectious Disease Research Institute
(IDRI), with interim data expected in the second half of this year.  In
addition to vaccines, Medicago is conducting research and development
in the area of biosimilar products.

About World Vaccine Congress and the Vaccine Industry Excellence Awards
The World Vaccine Congress remains the industry’s definitive vaccine
industry event for major vaccine players. Officially the
longest-running and largest vaccine industry event in North America,
the World Vaccine Congress delivers a forum where the ever-changing
dynamics of the vaccine industry are discussed and acted upon by the
industry’s most senior figures. The ViE Awards were created to honor
and generate recognition of the efforts, accomplishments, and positive
contributions of companies and individuals in the vaccine industry over
the previous 12 months.

About Medicago
Medicago is a clinical-stage biopharmaceutical company developing novel
vaccines and therapeutic proteins to address a broad range of
infectious diseases worldwide. The Company is committed to providing
highly effective and competitive vaccines and therapeutic proteins
based on its proprietary VLP and manufacturing technologies. Medicago
is a worldwide leader in the development of VLP vaccines using a
transient expression system which produces recombinant vaccine antigens
in plants. This technology has potential to offer more potent vaccines
with speed and cost advantages over competitive technologies, enabling
the development of a vaccine for testing in approximately one month
after the identification and reception of genetic sequences from a
pandemic strain. This production time frame has the potential to allow
vaccination of the population before the first wave of a pandemic, and
supply large volumes of vaccine antigens to the world market. Medicago
also intends to expand development into other areas such as biosimilars
and biodefense products where the benefits of our technologies can make
a significant difference. Additional information about Medicago is
available at www.medicago.com.

Forward Looking Statements
This news release includes certain forward-looking statements that are
based upon current expectations, which involve risks and uncertainties
associated with Medicago’s business and the environment in which the
business operates. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions “anticipate”, “believe”,
“plan”, “estimate”, “expect”, “intend”, and similar expressions to the
extent they relate to Medicago or its management. The forward-looking
statements are not historical facts, but reflect Medicago’s current
expectations regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainti
es that could cause actual results or events to differ materially from
current expectations, including the matters discussed under “Risk
Factors and Uncertainties” in Medicago’s Annual Information Form filed
on March 29, 2012 with the regulatory authorities. Medicago assumes no
obligation to update the forward-looking statements, or to update the
reasons why actual results could differ from those reflected in the
forward-looking statements.

SOURCE Medicago Inc.


Source: PR Newswire